US2008125489A1PendingUtilityA1

Methods and compositions for the treatment and prevention of lung disease

69
Assignee: MASSARO DONALDPriority: Apr 14, 1999Filed: Aug 28, 2007Published: May 29, 2008
Est. expiryApr 14, 2019(expired)· nominal 20-yr term from priority
Inventors:Donald MassaroGloria MassaroRoshantha A. Chandraratna
A61K 31/203A61K 31/07A61P 11/00A61K 31/00A61K 31/381
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for the treatment of lung disease such as emphysema and/or bronchopulmonary dysplasia in a mammal. Also disclosed are methods and compositions promoting the formation of alveolar septa and increasing the gas-exchange surface area of a mammalian lung, and for the prevention and/or treatment of alveolar destruction.

Claims

exact text as granted — not AI-modified
1 . A method for the treatment or inhibition of alveolar destruction in a mammal comprising administering a pharmaceutically effective amount of an RARγ agonist having specific RAR modulating activity, wherein said RARγ agonist is not an agonist of RARβ. 
     
     
         2 . The method of  claim 1  wherein said RARγ agonist is not specific to RARβ. 
     
     
         3 . The method of  claim 1  wherein said RARγ agonist is not specific to RARα. 
     
     
         4 . The method of  claim 1  wherein said RARγ agonist is not specific to RARβ or RARα. 
     
     
         5 . The method of  claim 1  wherein said composition further comprises said RARγ agonist in dissolved form. 
     
     
         6 . The method of  claim 5  wherein said RARγ agonist is not specific to RARβ. 
     
     
         7 . The method of  claim 5  wherein said RARγ agonist is not specific to RARα. 
     
     
         8 . The method of  claim 5  wherein said RARγ agonist is not specific to RARβ or RARα. 
     
     
         9 . A method for the treatment or inhibition of alveolar destruction in a mammal comprising the step of administering to said mammal a therapeutically effective amount of an RARγ agonist, wherein said RARγ agonist is not an agonist of RARα. 
     
     
         10 . The method of  claim 9 , wherein the RARγ agonist is an RARγ selective agonist. 
     
     
         11 . The method of  claim 9 , wherein the RARγ agonist has a K d  value for the RARγ receptor isotype that is at least 10 times lower than the K d  value for the RARβ receptor isotype. 
     
     
         12 . The method of  claim 9 , wherein the RARγ agonist has a K d  value for the RARγ receptor isotype that is at least 25 times lower than the K d  value for the RARα receptor isotype. 
     
     
         13 . The method of  claim 1 , wherein the RARγ agonist has a K d  value for the RARγ receptor isotype that is at least 10 times lower than the K d  value for the RARα receptor isotype. 
     
     
         14 . The method of  claim 1 , wherein the RARγ agonist has a K d  value the RARγ receptor isotype that is at least 25 times lower than the K d  value for the RARα receptor isotype. 
     
     
         15 . The method of  claim 9 , wherein the mammal is a human. 
     
     
         16 . The method of  claim 10 , wherein the mammal is a human. 
     
     
         17 . The method of  claim 11 , wherein the mammal is a human. 
     
     
         18 . The method of  claim 12 , wherein the mammal is a human. 
     
     
         19 . The method of  claim 13 , wherein the mammal is a human.

Join the waitlist — get patent alerts

Track US2008125489A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.